The safety and efficacy of Dymista has been demonstrated in several clinical studies involving over 4,000 patients, including a long-term safety study with more than 600 patients. Study results showed that Dymista provided a rapid and more complete symptomatic relief than standard treatment.
Dymista is a combination azelastine HCL and fluticasone propionate nasal spray formulation for the treatment of seasonal allergic rhinitis in patients 12 years and older. Dymista will be available in the US during the second half of 2012.
For more information call (732) 564-2200 or visit www.medapharma.us.